BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429 · Unknown status

Last updated 2026-05-28

This study observes how different second-line medications affect adults with type 2 diabetes to track heart-related events over time.

Status Unknown status The sponsor has not confirmed the status recently.

Type Observational

Participants 550,000 people Planned (estimated).

Who can join Ages 30+ · all sexes

Timeline Started 2021-07 · est. completion 2024-06

Where 5 sites · United States

What this study is testing ClinicalTrials.gov NCT05161429 ↗

Description as written by the study sponsor.

An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.

Treatments tested

DPP4 Drug

Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
GLP-1 receptor agonist Drug

Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
Basal Insulin Drug

degludec, detemir, glargine and NPH
SLGT2 Drug

Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
SU Drug

Sulfonylurea (SU) including glimepiride, glipizide, and glyburide

Main thing measured	4-point major adverse cardiac events (MACE)
Sponsor	Brigham and Women's Hospital
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05161429 ↗